Please login to the form below

Not currently logged in
Email:
Password:

Dinutuximab beta

This page shows the latest Dinutuximab beta news and features for those working in and with pharma, biotech and healthcare.

EUSA receives European green light for kidney cancer treatment Fotivda

EUSA receives European green light for kidney cancer treatment Fotivda

field.”. The UK-based group has also recently received another EU approval for the rare cancer drug dinutuximab beta as a treatment for high-risk neuroblastoma patients over the age of

Latest news

  • Keytruda and Opdivo backed for new uses in Europe Keytruda and Opdivo backed for new uses in Europe

    CHMP recommendations also include Trumenba, Dinutuximab beta and Refixia. MSD and Bristol-Myers Squibb (BMS) both picked up positive opinions for their PD-1 inhibitors from the EMA's advisory committee ... Apeiron Biologics also got the go-ahead for

More from news
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....